Notice Pursuant to the National Cooperative Research and Production Act of 1993-International Serum Industry Association, 17583 [07-1723]

Download as PDF Federal Register / Vol. 72, No. 67 / Monday, April 9, 2007 / Notices DEPARTMENT OF JUSTICE Antitrust Division sroberts on PROD1PC70 with NOTICES Notice Pursuant to the National Cooperative Research and Production Act of 1993—International Serum Industry Association Notice is hereby given that, on February 20, 2007, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), International Serum Industry Association (‘‘ISIA’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the name and principal place of business of the standards development organization and (2) the nature and scope of its standards development activities. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the name and principal place of business of the standards development organization is: International Serum Industry Association, McHenry, MD. The nature and scope of ISIA’s standards development activities are: to bring together, as members of the corporation, companies worldwide that are involved in the collection, sale, distribution, and processing of serum, and related companies. Serum is used in connection with research, diagnostic testing, and the development, sale and distribution of life sciences and biopharmaceutical products. The corporation’s purpose is to enhance the understanding, safety, use and general knowledge of serum and serum related products by adopting, promoting and encouraging policies by which its members will: (1) Establish common nomenclature and testing standards for use within the serum industry; (2) work together to address common regulatory issues (e.g. import/export); (3) address common concerns about health related issues; (4) develop industry quality standards for product and company performance; (5) develop a market wide understanding of sourcing and traceability and policies to standardize business practices; (6) develop a proactive industry, regulatory and world interface to educate, inform and advocate as appropriate, acting as a spokesperson for the international serum industry in North America and other parts of the world on government and public policy issues, especially those impacting worldwide trade; (7) VerDate Aug<31>2005 19:05 Apr 06, 2007 Jkt 211001 develop and implement standards of compliance to ensure that the industry is seen by all constituencies as operating at a high level of professional ethics; and (8) conduct such other activities, and adopt such other policies and practices, which are furtherance of the general objective of promoting uniform standards and reliability in the serum industry. Patricia A. Brink, Deputy Director of Operations, Antitrust Division. [FR Doc. 07–1723 Filed 4–6–07; 8:45 am] BILLING CODE 4410–11–M DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—LiMo Foundation Notice is hereby given that, on March 1, 2007, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (the ‘‘Act’’), LiMo Foundation (the ‘‘Foundation’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties to the venture are: Motorola, Inc., Libertyville, IL; NEC Corporation, Tokyo, JAPAN; Panasonic Mobile Communications Co., Ltd., Yokohama, JAPAN; Samsung Electronics Co., Ltd., Seoul, REPUBLIC OF KOREA; and Vodafone Group Services Limited, Newbury, Berkshire, UNITED KINGDOM. The nature and purpose of the Foundation is to develop a Linux-based, open mobile communication device software platform (the ‘‘Foundation Platform’’); to advance the creation, evolution, promotion, and support of the Foundation Platform; and to cultivate an ecosystem of complementary products, capabilities, and services, along with all other things ancillary to the foregoing purposes. Patricia A. Brink, Deputy Director of Operations, Antitrust Division. [FR Doc. 07–1727 Filed 4–6–07; 8:45 am] BILLING CODE 4410–11–M PO 00000 Frm 00109 Fmt 4703 Sfmt 4703 17583 DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—PXI Systems Alliance, Inc. Notice is hereby given that, on March 8, 2007, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4310 et seq. (‘‘the Act’’), PXI Systems Alliance, Inc. has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, TEGAM, Inc., Geneva, OH has been added as a party to this venture. Also, Global Test Solutions for Tabor Electronics, Yucaipa, CA and EADS North American Defense Test & Services, Irvine, CA have withdrawn as parties to this venture. In addition, B&B Technologies has changed its name to National Technical Systems-TSE, Albuquerque, NM. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and PXI Systems Alliance, Inc. intends to file additional written notifications disclosing all changes in membership. On November 22, 2000, PXI Systems Alliance, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on March 8, 2001 (66 FR 13971). The Last notification was filed with the Department on December 21, 2006. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on January 25, 2007 (72 FR 3416). Patricia A. Brink, Deputy Director of Operations, Antitrust Division. [FR Doc. 07–1726 Filed 4–6–07; 8:45 am] BILLING CODE 4410–11–M DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Telemanagement Forum Notice is hereby given that, on February 8, 2007, pursuant to Section E:\FR\FM\09APN1.SGM 09APN1

Agencies

[Federal Register Volume 72, Number 67 (Monday, April 9, 2007)]
[Notices]
[Page 17583]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-1723]



[[Page 17583]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--International Serum Industry Association

    Notice is hereby given that, on February 20, 2007, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), International Serum 
Industry Association (``ISIA'') has filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing (1) the name and principal place of business of 
the standards development organization and (2) the nature and scope of 
its standards development activities. The notifications were filed for 
the purpose of invoking the Act's provisions limiting the recovery of 
antitrust plaintiffs to actual damages under specified circumstances.
    Pursuant to Section 6(b) of the Act, the name and principal place 
of business of the standards development organization is: International 
Serum Industry Association, McHenry, MD. The nature and scope of ISIA's 
standards development activities are: to bring together, as members of 
the corporation, companies worldwide that are involved in the 
collection, sale, distribution, and processing of serum, and related 
companies. Serum is used in connection with research, diagnostic 
testing, and the development, sale and distribution of life sciences 
and biopharmaceutical products. The corporation's purpose is to enhance 
the understanding, safety, use and general knowledge of serum and serum 
related products by adopting, promoting and encouraging policies by 
which its members will: (1) Establish common nomenclature and testing 
standards for use within the serum industry; (2) work together to 
address common regulatory issues (e.g. import/export); (3) address 
common concerns about health related issues; (4) develop industry 
quality standards for product and company performance; (5) develop a 
market wide understanding of sourcing and traceability and policies to 
standardize business practices; (6) develop a proactive industry, 
regulatory and world interface to educate, inform and advocate as 
appropriate, acting as a spokesperson for the international serum 
industry in North America and other parts of the world on government 
and public policy issues, especially those impacting worldwide trade; 
(7) develop and implement standards of compliance to ensure that the 
industry is seen by all constituencies as operating at a high level of 
professional ethics; and (8) conduct such other activities, and adopt 
such other policies and practices, which are furtherance of the general 
objective of promoting uniform standards and reliability in the serum 
industry.

Patricia A. Brink,
Deputy Director of Operations, Antitrust Division.
[FR Doc. 07-1723 Filed 4-6-07; 8:45 am]
BILLING CODE 4410-11-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.